Emmanuel Edward Baetge

USPTO Granted Patents = 46 (Patent Applications = 15)

CIPO Patents = 10

EPO Patents = 15 (Patent Applications = 3)

Average Co-Inventor Count = 3.6

ph-index = 21

Forward Citations = 1,820(Granted Patents)

Location History:

St. Sulpice, CH (2016)
Sulpice, CH (2019)
San Diego, CA (US) (2015 - 2023)
Encinitas, CA (US) (2009 - 2024)

Company Filing History:

Dana-farber-cancer Institute Inc.

patents

5. 1 out of 2

Brigham and Women's Hopsital, Inc.

where one patent can have more than one assignee

Years Active: 2009-2024

Loading Chart...

46 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12173323 - Methods of using PDX1-positive pancreatic endoderm cells and endocrine precursor cells (2024-12-24),

2. 11896622 - Methods of producing pancreatic hormones (2024-02-13),

3. 11746323 - PDX1 positive foregut endoderm cells and methods of production (2023-09-05),

4. 11667889 - Methods of making human primitive ectoderm cells (2023-06-06),

5. 11660377 - Cryopreserved in vitro cell culture of human pancreatic progenitor cells (2023-05-30),

6. 11427805 - Methods of producing human foregut endoderm cells expressing PDX1 from human definitive endoderm (2022-08-30),

7. 11254916 - Methods of making and using PDX1-positive pancreatic endoderm cells (2022-02-22),

8. 10550367 - Methods of making human primitive ectoderm cells (2020-02-04),

9. 10517901 - Methods of lowering blood glucose levels in a mammal (2019-12-31),

10. 10465162 - Anterior endoderm cells and methods of production (2019-11-05),

11. 10421942 - Definitive endoderm (2019-09-24),

12. 10370645 - Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production (2019-08-06),

13. 10272179 - Encapsulation of pancreatic cells derived from human pluripotent stem cells (2019-04-30),

14. 10179902 - Methods of making human primitive ectoderm cells (2019-01-15),

15. 9980986 - Methods of producing pancreatic hormones (2018-05-29),

Title: Emmanuel Edward Baetge: Innovator in Pancreatic Cell Therapy

Introduction: Emmanuel Edward Baetge, based in Encinitas, California, is a prolific inventor with an impressive portfolio of 46 patents. His work primarily focuses on advancements in pancreatic endoderm and endocrine precursor cell technologies, contributing significantly to the field of regenerative medicine and potential therapies for diabetes and other endocrine disorders.

Latest Patents: Among his notable patents are innovative methods for utilizing PDX1-positive pancreatic endoderm cells and endocrine precursor cells. These patents disclose cell cultures and enriched cell populations of immature and mature pancreatic hormone-expressing cells. Furthermore, Baetge has developed methods for producing pancreatic hormone-expressing cells by differentiating pluripotent cells into competent endodermal cells capable of hormone secretion. His techniques also encompass transplantation methods of these cultured endodermal cells into organisms requiring endocrine cell therapy.

Career Highlights: Emmanuel Baetge has had a significant impact on the biotechnology sector, particularly in companies like Viacyte, Inc. and Cythera, Inc. His work at these institutions has paved the way for innovative treatments targeting diabetes and other related conditions, demonstrating his commitment to enhancing therapeutic options for patients.

Collaborations: Throughout his career, Baetge has collaborated with esteemed colleagues, including Kevin Allen D'Amour and Alan D Agulnick. These collaborations have enabled the sharing of knowledge and expertise, further advancing the development of effective cell-based therapies.

Conclusion: Emmanuel Edward Baetge stands out as a leading inventor in the realm of pancreatic cell therapies. His numerous patents and collaborations illustrate his dedication to innovation and improvement in medical treatments, positioning him as a key figure in contemporary biomedical research. As the field continues to evolve, Baetge's contributions will likely play a crucial role in shaping the future of endocrine therapies.

This text is generated by artificial intelligence and may not be accurate.